Cargando…

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors

BACKGROUND: Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors. Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouellet, Véronique, Ling, Tak Hay, Normandin, Karine, Madore, Jason, Lussier, Christian, Barrès, Véronique, Bachvarov, Dimcho, Rancourt, Claudine, Tonin, Patricia N, Provencher, Diane M, Mes-Masson, Anne-Marie
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2610034/
https://www.ncbi.nlm.nih.gov/pubmed/19032793
http://dx.doi.org/10.1186/1471-2407-8-346
_version_ 1782163077042536448
author Ouellet, Véronique
Ling, Tak Hay
Normandin, Karine
Madore, Jason
Lussier, Christian
Barrès, Véronique
Bachvarov, Dimcho
Rancourt, Claudine
Tonin, Patricia N
Provencher, Diane M
Mes-Masson, Anne-Marie
author_facet Ouellet, Véronique
Ling, Tak Hay
Normandin, Karine
Madore, Jason
Lussier, Christian
Barrès, Véronique
Bachvarov, Dimcho
Rancourt, Claudine
Tonin, Patricia N
Provencher, Diane M
Mes-Masson, Anne-Marie
author_sort Ouellet, Véronique
collection PubMed
description BACKGROUND: Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors. Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined. METHODS: In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1). RESULTS: Statistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003). When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01). Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001). We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants. CONCLUSION: This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective.
format Text
id pubmed-2610034
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26100342008-12-25 Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors Ouellet, Véronique Ling, Tak Hay Normandin, Karine Madore, Jason Lussier, Christian Barrès, Véronique Bachvarov, Dimcho Rancourt, Claudine Tonin, Patricia N Provencher, Diane M Mes-Masson, Anne-Marie BMC Cancer Research Article BACKGROUND: Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors. Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined. METHODS: In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1). RESULTS: Statistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003). When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01). Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001). We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants. CONCLUSION: This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective. BioMed Central 2008-11-26 /pmc/articles/PMC2610034/ /pubmed/19032793 http://dx.doi.org/10.1186/1471-2407-8-346 Text en Copyright © 2008 Ouellet et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ouellet, Véronique
Ling, Tak Hay
Normandin, Karine
Madore, Jason
Lussier, Christian
Barrès, Véronique
Bachvarov, Dimcho
Rancourt, Claudine
Tonin, Patricia N
Provencher, Diane M
Mes-Masson, Anne-Marie
Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
title Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
title_full Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
title_fullStr Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
title_full_unstemmed Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
title_short Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
title_sort immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2610034/
https://www.ncbi.nlm.nih.gov/pubmed/19032793
http://dx.doi.org/10.1186/1471-2407-8-346
work_keys_str_mv AT ouelletveronique immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT lingtakhay immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT normandinkarine immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT madorejason immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT lussierchristian immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT barresveronique immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT bachvarovdimcho immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT rancourtclaudine immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT toninpatrician immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT provencherdianem immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors
AT mesmassonannemarie immunohistochemicalprofilingofbenignlowmalignantpotentialandlowgradeserousepithelialovariantumors